Antagonistic and antibacterial activity of Lactobacillus rhamnosus HN001 and Lactobacillus acidophilus La-14 included in the oral probiotic

封面


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅存取

详细

BACKGROUND: A microbial imbalance in the vaginal biotope leads to the development of vaginal infections and is associated with urinary tract infections. The ineffectiveness of the therapy and the frequent recurrence of these infections are important reasons for searching for alternative treatment strategies. A progressive solution to this issue has been the use of oral probiotics with a targeted effect on the intestinal and vaginal microflora.

AIM: The aim of this study was to evaluate the antagonistic and antibacterial activity of the probiotic strains Lactobacillus rhamnosus HN001 and Lactobacillus acidophilus La-14, which are the components of the oral probiotic, against opportunistic microorganisms of intestinal origin, while assessing the sensitivity of these strains to antimicrobial drugs.

MATERIALS AND METHODS: The probiotic strains Lactobacillus rhamnosus HN001 and Lactobacillus acidophilus La-14 included in the oral probiotic Duogynal® were cultivated and the grown colonies were identified using the matrix-assisted laser desorption/ionization time-of-flight mass spectrometry method (Bruker Daltonics GmbH & Co., Germany). To study the antagonism of the probiotic strains of lactobacilli and opportunistic pathogenic microorganisms, the following 11 clinical isolates were collected: Escherichia coli (two isolates), Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter asburiae, Proteus mirabilis, Citrobacter freundii, Staphylococcus aureus, Enterococcus faecalis, Streptococcus agalactiae, and Candida albicans. To assess the sensitivity of the probiotic strains to antimicrobial drugs, the Gram Positive AST panel (Autobio Diagnostics Co., Ltd, China) was used.

RESULTS: When the microorganisms were co-cultivated with the probiotic lactobacilli (Lactobacillus rhamnosus HN001 and Lactobacillus acidophilus La-14), we noted a decrease in pH and the death of opportunistic microorganisms such as Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter asburiae, Proteus mirabilis, Citrobacter freundii, Staphylococcus aureus, Enterococcus faecalis, and Streptococcus agalactiae, as well as yeast-like fungi Candida albicans. When studying antibiotic resistance, it was found that the both strains of lactobacilli were resistant to ampicillin, vancomycin, daptomycin, clindamycin, linezolid, moxifloxacin, nitrofurantoin, oxacillin, oritavancin, penicillin, rifampin, teicoplanin, tigecycline, trimethoprim/sulfamethoxazole, cefoxitin, ceftarolin, and ciprofloxacin.

CONCLUSIONS: The oral probiotic, which contains a combination of two lactobacilli (Lactobacillus rhamnosus HN001 and Lactobacillus acidophilus La-14), has pronounced antagonistic activity against opportunistic microorganisms. These strains are resistant to most antibacterial drugs used in widespread clinical practice, which may be the basis for recommending the use of this probiotic drug together with prescribed antibiotics for prevention of vaginal or intestinal dysbiosis.

作者简介

Olga Budilovskaya

The Research Institute of Obstetrics, Gynecology and Reproductology named after D.O. Ott; Saint Petersburg State Pediatric Medical University

编辑信件的主要联系方式.
Email: o.budilovskaya@gmail.com
ORCID iD: 0000-0001-7673-6274
SPIN 代码: 7603-6982

MD, Cand. Sci. (Med.)

俄罗斯联邦, Saint Petersburg; Saint Petersburg

Elena Spasibova

The Research Institute of Obstetrics, Gynecology and Reproductology named after D.O. Ott; Saint Petersburg State Pediatric Medical University

Email: elena.graciosea@gmail.com
ORCID iD: 0009-0002-6070-4651
SPIN 代码: 3585-8770
俄罗斯联邦, Saint Petersburg; Saint Petersburg

Kira Shalepo

The Research Institute of Obstetrics, Gynecology and Reproductology named after D.O. Ott; Saint Petersburg State Pediatric Medical University

Email: 2474151@mail.ru
ORCID iD: 0000-0002-3002-3874
SPIN 代码: 2527-7198

MD, Cand. Sci. (Med.)

俄罗斯联邦, Saint Petersburg; Saint Petersburg

Tatiana Khusnutdinova

The Research Institute of Obstetrics, Gynecology and Reproductology named after D.O. Ott; Saint Petersburg State Pediatric Medical University

Email: husnutdinovat@yandex.ru
ORCID iD: 0000-0002-2742-2655
SPIN 代码: 9533-9754

MD, Cand. Sci. (Med.)

俄罗斯联邦, Saint Petersburg; Saint Petersburg

Anna Krysanova

The Research Institute of Obstetrics, Gynecology and Reproductology named after D.O. Ott; Saint Petersburg State Pediatric Medical University

Email: krusanova.anna@mail.ru
ORCID iD: 0000-0003-4798-1881
SPIN 代码: 2438-0230

MD, Cand. Sci. (Med.)

俄罗斯联邦, Saint Petersburg; Saint Petersburg

Anna Siniakova

The Research Institute of Obstetrics, Gynecology, and Reproductology named after D.O. Ott

Email: annakizeeva@yandex.ru
ORCID iD: 0000-0003-3094-665X
SPIN 代码: 7795-8364

MD, Cand. Sci. (Med.)

俄罗斯联邦, Saint Petersburg

Olesya Bespalova

The Research Institute of Obstetrics, Gynecology and Reproductology named after D.O. Ott

Email: shiggerra@mail.ru
ORCID iD: 0000-0002-6542-5953
SPIN 代码: 4732-8089

MD, Dr. Sci. (Med.)

俄罗斯联邦, Saint Petersburg

Alevtina Savicheva

The Research Institute of Obstetrics, Gynecology and Reproductology named after D.O. Ott; Saint Petersburg State Pediatric Medical University

Email: savitcheva@mail.ru
ORCID iD: 0000-0003-3870-5930
SPIN 代码: 8007-2630

MD, Dr. Sci. (Med.), Professor, Honored Worker of Science of the Russian Federation

俄罗斯联邦, Saint Petersburg; Saint Petersburg

参考

  1. Döderlein A. Das scheidensekret und seine bedeutung für das puerperalfieber. Leipzig: Besold; 1892. (in Ger.)
  2. Zheng J, Wittouck S, Salvetti E, et al. A taxonomic note on the genus Lactobacillus: description of 23 novel genera, emended description of the genus Lactobacillus Beijerinck 1901, and union of Lactobacillaceae and Leuconostocaceae. Int J Syst Evol Microbiol. 2020;70(4):2782–2858. doi: 10.1099/ijsem.0.004107
  3. Pramanick R, Mayadeo N, Warke H, et al. Vaginal microbiota of asymptomatic bacterial vaginosis and vulvovaginal candidiasis: are they different from normal microbiota? Microb Pathog. 2019;134. doi: 10.1016/j.micpath.2019.103599
  4. Donders GG, Van Calsteren K, Bellen G, et al. Predictive value for preterm birth of abnormal vaginal flora, bacterial vaginosis and aerobic vaginitis during the first trimester of pregnancy. BJOG. 2009;116(10):1315–1324. doi: 10.1111/j.1471-0528.2009.02237.x
  5. Stapleton AE. The vaginal microbiota and urinary tract infection. Microbiol Spectr. 2016;4(6). doi: 10.1128/microbiolspec.UTI-0025-2016
  6. Gupta V, Nag D, Garg P. Recurrent urinary tract infections in women: how promising is the use of probiotics? Indian J Med Microbiol. 2017;35(3):347–354. doi: 10.4103/ijmm.IJMM_16_292
  7. Asadi Karam MR, Habibi M, Bouzari S. Urinary tract infection: pathogenicity, antibiotic resistance and development of effective vaccines against Uropathogenic Escherichia coli. Mol Immunol. 2019;108:56–67. doi: 10.1016/j.molimm.2019.02.007
  8. Kline KA, Lewis AL. Gram-positive uropathogens, polymicrobial urinary tract infection, and the emerging microbiota of the urinary tract. Microbiol Spectr. 2016;4(2). doi: 10.1128/microbiolspec.UTI-0012-2012
  9. Kirjavainen PV, Pautler S, Baroja ML, et al. Abnormal immunological profile and vaginal microbiota in women prone to urinary tract infections. Clin Vaccine Immunol. 2009;16(1):29–36. doi: 10.1128/CVI.00323-08
  10. Muhleisen AL, Herbst-Kralovetz MM. Menopause and the vaginal microbiome. Maturitas. 2016;91:42–50. doi: 10.1016/j.maturitas.2016.05.015
  11. Prevention of early-onset neonatal group B streptococcal disease: green-top Guideline No. 36. BJOG. 2017;124(12):e280–e305. doi: 10.1111/1471-0528.14821
  12. Khvan VO, Shipitsyna EV, Zatsiorskaya SL, et al. Frequency and risk factors of colonization of pregnant women with group B streptococci. Journal of Obstetrics and Women’s Diseases. 2017;66(6):44–58. EDN: KNJTFE doi: 10.17816/JOWD66644-58
  13. Money D, Allen VM. The prevention of early-onset neonatal group B streptococcal disease. J Obstet Gynaecol Can. 2013;35(10):939–948. doi: 10.1016/S1701-2163(15)30818-5
  14. Bradshaw CS, Morton AN, Hocking J., et al. High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. J Infect Dis. 2006;193(11):1478–1486. doi: 10.1086/503780
  15. Arastehfar A, Kargar ML, Mohammadi SR et al. A high rate of recurrent vulvovaginal candidiasis and therapeutic failure of azole derivatives among iranian women. Front Microbiol. 2021;12. doi: 10.3389/fmicb.2021.655069
  16. Renard J, Ballarini S, Mascarenhas T, et al. Recurrent lower urinary tract infections have a detrimental effect on patient quality of life: a prospective, observational study. Infect Dis Ther. 2015;4(1):125–135. doi: 10.1007/s40121-014-0054-6
  17. Kolousova KA, Shipitsyna EV, Shalepo KV, et al. Virulence and pathogenicity factors of S. agalactiae strains isolated from pregnant women and newborns. Journal of Obstetrics and Women’s Diseases. 2021;70(5):15–22. EDN: OATELN doi: 10.17816/JOWD75671
  18. Khusnutdinova TA, Shipitsyna EV, Krysanova AA, et al. Profiles and genetic determinants of antimicrobial resistance in pathogens causing community-acquired urinary tract infections in reproductive-age women. Medical alphabet. 2021;(18):12–15. EDN: FXXPWN doi: 10.33667/2078-5631-2021-18-12-15
  19. Willing BP, Russell SL, Finlay BB. Shifting the balance: antibiotic effects on host-microbiota mutualism. Nat Rev Microbiol. 2011;9(4):233–243. doi: 10.1038/nrmicro2536
  20. Agamennone V, Krul CAM, Rijkers G, et al. A practical guide for probiotics applied to the case of antibiotic-associated diarrhea in the Netherlands. BMC Gastroenterol. 2018;18(1):103. doi: 10.1186/s12876-018-0831-x
  21. Larcombe S, Hutton ML, Lyras D. Involvement of bacteria other than clostridium difficile in antibiotic-associated Diarrhoea. Trends Microbiol. 2016;24(6):463–476. doi: 10.1016/j.tim.2016.02.001
  22. Shah T, Baloch Z, Shah Z, et al. The intestinal microbiota: impacts of antibiotics therapy, colonization resistance, and diseases. Int J Mol Sci. 2021;22(12). doi: 10.3390/ijms22126597
  23. Sanders ME, Merenstein D, Merrifield CA, et al. Probiotics for human use. Nutrition bulletin. 2018;43(3):212–225. doi: 10.1111/nbu.12334
  24. Hempe LS, Newberry SJ, Maher AR, et al. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. JAMA. 2012;307(18):1959–1969. doi: 10.1001/jama.2012.3507
  25. Marrazzo JM, Fiedler TL, Srinivasan S, et al. Extravaginal reservoirs of vaginal bacteria as risk factors for incident bacterial vaginosis. J Infect Dis. 2012;205(10):1580–1588. doi: 10.1093/infdis/jis242
  26. Bastani P, Homayouni A, Tabrizian VG, et al. Dairy probiotic foods and bacterial vaginosis: a review on mechanism of action. In: Rigobelo E, editor. Probiotics. IntechOpen; 2012. doi: 10.5772/50083
  27. Leonova MV. Probiotics in the treatment of vaginal infections: efficacy from the perspective of evidence-based medicine. Medical Council. 2020;(13):148–154. EDN: COCSOB doi: 10.21518/2079-701X-2020-13-148-154
  28. Reid G. The scientific basis for probiotic strains of Lactobacillus. Appl Environ Microbiol. 1999;65(9):3763–3766. doi: 10.1128/AEM.65.9.3763-3766.1999
  29. Conway PL, Gorbach SL, Goldin BR., et al. Survival of lactic acid bacteria in the human stomach and adhesion to intestinal cells. J Dairy Sci. 1987;70(1):1–12. doi: 10.3168/jds.S0022-0302(87)79974-3
  30. Santos CMA, Pires MCV, Leao TL, et al. Selection of Lactobacillus strains as potential probiotics for vaginitis treatment. Microbiology. 2016;162(7):1195–1207. doi: 10.1099/mic.0.000302
  31. Mogha KV, Prajapati JB. Probiotics for treating bacterial vaginosis. Rev Med Microbiol. 2016;27(3):87–94. doi: 10.1097/MRM.0000000000000080
  32. Bertuccini L, Russo R, Iosi F, et al. Effects of Lactobacillus rhamnosus and Lactobacillus acidophilus on bacterial vaginal pathogens. Int J Immunopathol Pharmacol. 2017;30(2):163–167. doi: 10.1177/0394632017697987
  33. Russo R, Superti F, Karadja E, et al. Randomised clinical trial in women with Recurrent Vulvovaginal Candidiasis: efficacy of probiotics and lactoferrin as maintenance treatment. Mycoses. 2019;62(4):328–335. doi: 10.1111/myc.12883
  34. De Alberti D, Russo R, Terruzzi F, et al. Lactobacilli vaginal colonisation after oral consumption of Respecta(®) complex: a randomised controlled pilot study. Arch Gynecol Obstet. 2015;292(4):861–867. doi: 10.1007/s00404-015-3711-4
  35. Minkina GN, Bondarenko KR, Selikhova MS, et al. Renaissance of the vaginal microbiota: reframing clinical paradigms. Russian Journal of Woman and Child Health. 2022;5(4):303–308 EDN: PVHVKW doi: 10.32364/2618-8430-2022-5-4-303-308
  36. ChenYC, LeeWC, ChuangYC. Emerging non-antibiotic options targeting uropathogenic mechanisms for recurrent uncomplicated urinary tract infection. Int J Mol Sci. 2023;24(8):7055. doi: 10.3390/ijms24087055
  37. Bhatia M, Mitsi V, Court L. The outcomes of pregnancies with reduced fetal movements: A retrospective cohort study. Acta Obstet Gynecol Scand. 2019;98:1450–1454. doi: 10.1111/aogs.13671
  38. Siniakova AA, Shipitsyna EV, Budilovskaya OV, et al. The efficiency of treatment of vaginal infections in women with a history of miscarriage. Journal of Obstetrics and Women’s Diseases. 2019;68(5):63–74. EDN: YHKWUN doi: 10.17816/JOWD68563-74
  39. Olsen P, Williamson M, Traynor V et al. The impact of oral probiotics on vaginal group B streptococcal colonisation rates in pregnant women: a pilot randomised control study. Women Birth. 2018;31(1):31–37. doi: 10.1016/j.wombi.2017.06.012
  40. Brotman RM, Shardell MD, Gajer P, et al. Association between the vaginal microbiota, menopause status, and signs of vulvovaginal atrophy. Menopause. 2018;25(11):1321–1330. doi: 10.1097/GME.0000000000001236
  41. Mastromarino P, Vitali B, Mosca L. Bacterial vaginosis: a review on clinical trials with probiotics. New Microbiol. 2013;36(3):229–238.
  42. Nader-Macías MEF, De Gregorio PR, Silva JA. Probiotic lactobacilli in formulas and hygiene products for the health of the urogenital tract. Pharmacol Res Perspect. 2021;9(5). doi: 10.1002/prp2.787
  43. .Szczerbiec D, Słaba M, Torzewska A. Substances secreted by Lactobacillus spp. from the urinary tract microbiota play a protective role against Proteus mirabilis infections and their complications. Int J Mol Sci. 2023;25(1):103. doi: 10.3390/ijms25010103
  44. Leccese Terraf MC, Juarez Tomás MS, Rault L, et al. In vitro effect of vaginal lactobacilli on the growth and adhesion abilities of uropathogenic Escherichia coli. Arch Microbiol. 2017;199(5):767–774. doi: 10.1007/s00203-016-1336-z
  45. Wang C, Fan A, Li H, et al. Vaginal bacterial profiles of aerobic vaginitis: a case-control study. Diagn Microbiol Infect. Dis. 2020;96. doi: 10.1016/j.diagmicrobio.2019.114981
  46. Zhang Z, Wang X, Li F. An exploration of alginate oligosaccharides modulating intestinal inflammatory networks via gut microbiota. Front Microbiol. 2023;14. doi: 10.3389/fmicb.2023.1072151
  47. Goodman C, Keating G, Georgousopoulou E, et al. Probiotics for the prevention of antibiotic-associated diarrhoea: a systematic review and meta-analysis. BMJ Open. 2021;11(8). doi: 10.1136/bmjopen-2020-043054

补充文件

附件文件
动作
1. JATS XML
下载
2. Fig. 1. Growth of Lactobacillus acidophilus (1), Lactobacillus rhamnosus (2) and the both components of the oral probiotic (1 + 2), on chromogenic agar

下载 (59KB)
索引源数据
3. Fig. 2. Results of co-cultivation of bacteria and the lactobacilli that are the components of the oral probiotic

下载 (382KB)
索引源数据
4. Fig. 3. Results of co-cultivation of Candida albicans and the lactobacilli that are the components of the oral probiotic: a, Candida albicans on chromogenic agar; b, growth of Candida albicans and lactobacilli when co-cultured with one of the lactobacilli strains and inhibition of yeast-like fungi growth when the two strains were added simultaneously

下载 (94KB)
索引源数据

版权所有 © Eсо-Vector, 2024

许可 URL: https://eco-vector.com/for_authors.php#07

Согласие на обработку персональных данных с помощью сервиса «Яндекс.Метрика»

1. Я (далее – «Пользователь» или «Субъект персональных данных»), осуществляя использование сайта https://journals.rcsi.science/ (далее – «Сайт»), подтверждая свою полную дееспособность даю согласие на обработку персональных данных с использованием средств автоматизации Оператору - федеральному государственному бюджетному учреждению «Российский центр научной информации» (РЦНИ), далее – «Оператор», расположенному по адресу: 119991, г. Москва, Ленинский просп., д.32А, со следующими условиями.

2. Категории обрабатываемых данных: файлы «cookies» (куки-файлы). Файлы «cookie» – это небольшой текстовый файл, который веб-сервер может хранить в браузере Пользователя. Данные файлы веб-сервер загружает на устройство Пользователя при посещении им Сайта. При каждом следующем посещении Пользователем Сайта «cookie» файлы отправляются на Сайт Оператора. Данные файлы позволяют Сайту распознавать устройство Пользователя. Содержимое такого файла может как относиться, так и не относиться к персональным данным, в зависимости от того, содержит ли такой файл персональные данные или содержит обезличенные технические данные.

3. Цель обработки персональных данных: анализ пользовательской активности с помощью сервиса «Яндекс.Метрика».

4. Категории субъектов персональных данных: все Пользователи Сайта, которые дали согласие на обработку файлов «cookie».

5. Способы обработки: сбор, запись, систематизация, накопление, хранение, уточнение (обновление, изменение), извлечение, использование, передача (доступ, предоставление), блокирование, удаление, уничтожение персональных данных.

6. Срок обработки и хранения: до получения от Субъекта персональных данных требования о прекращении обработки/отзыва согласия.

7. Способ отзыва: заявление об отзыве в письменном виде путём его направления на адрес электронной почты Оператора: info@rcsi.science или путем письменного обращения по юридическому адресу: 119991, г. Москва, Ленинский просп., д.32А

8. Субъект персональных данных вправе запретить своему оборудованию прием этих данных или ограничить прием этих данных. При отказе от получения таких данных или при ограничении приема данных некоторые функции Сайта могут работать некорректно. Субъект персональных данных обязуется сам настроить свое оборудование таким способом, чтобы оно обеспечивало адекватный его желаниям режим работы и уровень защиты данных файлов «cookie», Оператор не предоставляет технологических и правовых консультаций на темы подобного характера.

9. Порядок уничтожения персональных данных при достижении цели их обработки или при наступлении иных законных оснований определяется Оператором в соответствии с законодательством Российской Федерации.

10. Я согласен/согласна квалифицировать в качестве своей простой электронной подписи под настоящим Согласием и под Политикой обработки персональных данных выполнение мною следующего действия на сайте: https://journals.rcsi.science/ нажатие мною на интерфейсе с текстом: «Сайт использует сервис «Яндекс.Метрика» (который использует файлы «cookie») на элемент с текстом «Принять и продолжить».